Compare AbCellera Biologics Inc (ABCL) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Annaly Capital Management, Inc. — how do they compare? AbCellera Biologics Inc trades at $10.32 (market cap $2.99B), while Annaly Capital Management, Inc. trades at $23.11 (market cap $17.44B). The key difference: Annaly Capital Management, Inc. is far larger — about 5.8× AbCellera Biologics Inc's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NLY | |
|---|---|---|
Market Cap | $2.99B | $17.44B |
Sector | Health | Financials |
52-Week High | $9.76 | $24.40 |
52-Week Low | $2.78 | $20.21 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
NLY trades at $23.23, up 1.4% with strong technical momentum as moving averages signal bullish sentiment. The stock demonstrates robust fundamentals with a low P/E of 5.59 and impressive 92.77% net income margin, supported by three consecutive quarterly earnings beats. Recent analyst upgrades and institutional buying reflect growing confidence in the mortgage REIT's housing finance strategy and dividend sustainability.
Outlook remains positive with consensus price target of $24.50 offering 5.5% upside potential. Key opportunities include the 13%+ dividend yield and diversified housing finance platform, while risks center on interest rate volatility and the company's high leverage ratio of 23.55. Earnings growth momentum and institutional support provide catalysts for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
